

PC22039A
Terminal Disclaimer For Appln. No. **10/601,355**

Certificate of Transmission (37 C.F.R. §1.8);
I hereby certify that this correspondence is being
electronically transmitted via **EFS-Web** to the United
States Patent and Trademark Office, **Commissioner For
Patents**, on this **5th** day of **June** 2007.

s/ /Donna Di Maccio/
Donna Di Maccio

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Anthony David Auffret, et al.

Group Art Unit: 1751

Serial No.: 10/601,355

Examiner: Susannah Chung

Confirmation No: 7465

Filed: June 23, 2003

**For: PROCESS FOR CONTROLLING THE
HYDRATE MIX OF A COMPOUND**

TERMINAL DISCLAIMER

Madam:

Pfizer Inc., owner of all title and interest in the above-identified application by virtue of an Assignment recorded at Reel 013334, Frame 0282, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on this application that would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154-156 and 173 as shortened by any terminal disclaimer filed before the grant of U.S. Patent No. 6,977,302 issued on prior U.S. Patent Application Serial No. 10/810,100, filed on March 26, 2004. The owner agrees that any patent granted on the present application shall be enforceable only for and during such period that it and U.S. Patent No. 6,977,302 are commonly owned. A copy of the Notice of Recordation for the patent family of US Patent No. 6,977,302, having Reel/Frame No. of 9828/0484 is attached. This agreement runs with any patent granted on the present application and is binding on the grantee and its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the present application that would extend to the expiration date of the full statutory term as term defined in 35 U.S.C. §§ 154-156 and 173 of the patent, as presently

shortened by any terminal disclaimer, in the event that such granted patent: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321; has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated before the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Please charge any fees not submitted herewith required for filing this terminal disclaimer, including the fee under 37 C.F.R. § 1.20(d), to Deposit Account No. 16-1445.

This is a submission on behalf of the owner. The undersigned is empowered to act on behalf of the owner.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true. I further declare that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Respectfully submitted,

Date: June 5, 2007

/Elsa Djuardi/
Elsa Djuardi, Ph.D.
Attorney For Applicants
Registration No. 45,963

Pfizer Inc
Patent Dept.
10555 Science Center Drive
San Diego, California 92121
Phone: (858) 638-6117
Fax: (858) 678-8233